Avanafil-13C,d3
Product Specifications
UNSPSC Description
Avanafil-13C,d3 is the 13C- and deuterium labeled Avanafil.
Target Antigen
Isotope-Labeled Compounds; Phosphodiesterase (PDE)
Type
Isotope-Labeled Compounds
Related Pathways
Metabolic Enzyme/Protease;Others
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Solubility
10 mM in DMSO
Smiles
ClC1=C(O[13C]([2H])([2H])[2H])C=CC(CNC2=C(C(NCC3=NC=CC=N3)=O)C=NC(N4[C@H](CO)CCC4)=N2)=C1
Molecular Weight
487.96
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.|[2]Kotera J, et al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012 Aug;188(2):668-74.|[3]Mochida H, et al. Avanafil, a highly selective phosphodiesterase type 5 inhibitor for erectile dysfunction, shows good safety profiles for retinal function and hemodynamics in anesthetized dogs. J Urol. 2013 Aug;190(2):799-806.|[4]Wang R, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med. 2012 Aug;9(8):2122-9.
Shipping Conditions
Room temperature
Clinical Information
No Development Reported
CAS Number
2738376-89-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
RC203282L1V 200 µL
FAM18B (TVP23B) (NM_016078) Human Tagged ORF Clone Lentiviral Particle
Ask
View Details 
